Matrix-Risk-Control-Ltd near Mitchell MB (887 Result(s))

The Manitoba Ozone Protection Association has achieved overwhelming success both in the public's eye and that of industry and governments across Canada. Surely in part, this has been due to the millions of dollars that were spent and invested by Manitoba industry to provide employee training and new equipment installations. This, in an effort to ensure compliance with the requirements of the Manitoba regulation. A good indication of the success of the program is the decrease that has been noted by wholesalers and suppliers in the purchase of virgin ODS's.Each of the prime objectives training & education, outreach, membership and liaison activities together with the activities related to the development and implementation have been highlighted in this report and can be detailed in further by contacting Mark Miller at MOPIA.

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.

Saving Lives Through Early Disease DiagnosisMiraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs. Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians.The Miraculins AdvantageProducts & ProgramsMiraculins is dedicated to the development and commercialization of diagnostic tests and risk assessment technologies for diseases and conditions that are lacking highly sensitive and specific tests.